Gastroenterology · Antispasmodic
The FDA's approval of Dicyclomine Hydrochloride ANDA216515 is significant as it strengthens Rubicon Research's competitive position in the gastroenterology market. Pharma strategy teams should closely monitor market dynamics and competitor responses to this new entry to inform future strategic decisions.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/24/2026, 6:03:38 AM
Assessment confidence: 70% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of Dicyclomine Hydrochloride ANDA216515 is significant as it strengthens Rubicon Research's competitive position in the gastroenterology market. Pharma strategy teams should closely monitor market dynamics and competitor responses to this new entry to inform future strategic decisions. Regulatory context from FDA (FDA AP — DICYCLOMINE HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 17 ranked evidence items (10 high-relevance).
Portfolio teams should assess the market dynamics post-approval and consider strategies to leverage this new entry. The strongest clinical anchor is Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine. In Gastroenterology · Antispasmodic, 7 regulatory and 3 competitive items passed relevance filtering for Dicyclomine Hydrochloride.
The most relevant competitive pressure comes from FDA Grants Priority Review for Novartis' Fabhalta (Ipacopan Hydrochloride) (Humanexa Signals) — sponsor/company relevance (novartis). Secondary pressure from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy. This approval may enhance Rubicon Research's position in the gastroenterology market, potentially impacting competitors in the antispasmodic segment.
Regulatory risk is concentrated around FDA AP — DICYCLOMINE HYDROCHLORIDE (ORIG) (FDA). Entity match (dicyclomine hydrochloride); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, which may influence future regulatory strategies for similar products within the portfolio.
FDA AP — DICYCLOMINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (dicyclomine hydrochloride); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — MOXIFLOXACIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — PITOLISANT HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceLong-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceCollection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Grants Priority Review for Novartis' Fabhalta (Ipacopan Hydrochloride)
Humanexa Signalshigh relevance
Sponsor/company relevance (Novartis)
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Approval for Ferric Carboxymaltose by Mylan Labs
Humanexa Signalsmedium relevance
Moderate corpus alignment
Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceTargeting post-translational modifications by traditional Chinese medicine in cerebral ischemia-reperfusion injury: Recent advances.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceInterim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of Dicyclomine Hydrochloride ANDA216515 is significant as it strengthens Rubicon Research's competitive position in the gastroenterology market. Pharma strategy teams should closely monitor market dynamics and competitor responses to this new entry to inform future strategic decisions.
This approval could lead to increased market share for Rubicon Research, potentially affecting revenue streams for existing competitors in the antispasmodic market.
The approval indicates compliance with FDA standards, which may influence future regulatory strategies for similar products within the portfolio.
Monitor market uptake and any competitive responses from other antispasmodic drug manufacturers.
Track for follow-up milestones; no immediate action required.